UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

The New England journal of medicine, 2018-03, Vol.378 (12), p.1107-1120

2018

Volltextzugriff (PDF)

A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors

Annals of oncology, 2006-08, Vol.17 (8), p.1320-1327

2006

Volltextzugriff (PDF)

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

The New England journal of medicine, 2019-06, Vol.380 (23), p.2225-2236

2019

Volltextzugriff (PDF)

69 ABT-199, a Selective Small Molecule Inhibitor of Bcl-2, Exhibits Efficacy in Bcl-2 Dependent Malignancies While Sparing Platelets

European journal of cancer (1990), 2012-11, Vol.48, p.23-23

2012

Volltextzugriff (PDF)

Phase I Interim Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) Monotherapy for Relapsed/Refractory (R/R) Multiple Myeloma (MM)

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e81-e82

2015

Volltextzugriff (PDF)

Phase 1b Interim Results: Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib (BTZ) and Dexamethasone (Dex) in Relapsed/Refractory (R/R) Multiple Myeloma (MM)

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e272-e273

2015

Volltextzugriff (PDF)

Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: A safe combination

European journal of cancer (1990), 2006-03, Vol.42 (4), p.467-472

2006

Volltextzugriff (PDF)

Investigation of the Immunogenicity of a Protein Drug Using Equilibrium Dialysis and Liquid Chromatography Tandem Mass Spectrometry Detection

Analytical chemistry (Washington), 2005-09, Vol.77 (17), p.5529-5533

2005

Volltextzugriff (PDF)

Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2

Cancer research (Chicago, Ill.), 2000-03, Vol.60 (5), p.1189-1192

2000

Volltextzugriff (PDF)

Phase I Study of Eniluracil, a Dihydropyrimidine Dehydrogenase Inactivator, and Oral 5-Fluorouracil with Radiation Therapy in Patients with Recurrent or Advanced Head and Neck Cancer

Clinical cancer research, 1999-02, Vol.5 (2), p.291-298

1999

Volltextzugriff (PDF)

Effect of Endothelin-A Receptor Blockade With Atrasentan on Tumor Progression in Men With Hormone-Refractory Prostate Cancer: A Randomized, Phase II, Placebo-Controlled Trial

Journal of clinical oncology, 2003-02, Vol.21 (4), p.679-689

2003

Volltextzugriff (PDF)

Concomitant Chemoradiotherapy as Primary Therapy for Locoregionally Advanced Head and Neck Cancer

Journal of clinical oncology, 2000-04, Vol.18 (8), p.1652-1661

2000

Volltextzugriff (PDF)

Irinotecan Activation by Human Carboxylesterases in Colorectal Adenocarcinoma Cells

Clinical cancer research, 2002-08, Vol.8 (8), p.2696-2700

2002

Volltextzugriff (PDF)

Phase II studies of bryostatin-1 in patients with advanced sarcoma and advanced head and neck cancer

Investigational new drugs, 2001-01, Vol.19 (3), p.249-254

2001

Volltextzugriff (PDF)

Differential activating and deactivating effects of natural ryanodine congeners on the calcium release channel of sarcoplasmic reticulum: evidence for separation of effects at functionally distinct sites

Molecular pharmacology, 1993-08, Vol.44 (2), p.412-421

1993

Volltextzugriff (PDF)

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Thrombospondin-1–Mimetic Angiogenesis Inhibitor ABT-510 in Patients With Advanced Cancer

Journal of clinical oncology, 2005-08, Vol.23 (22), p.5188-5197

2005

Volltextzugriff (PDF)

Population pharmacokinetic (PK) analysis of ABT-869 in solid tumors and acute myelogenous leukemia (AML) patients

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.3567-3567

2009

Volltextzugriff (PDF)

Structural Determinants of High-Affinity Binding of Ryanoids to the Vertebrate Skeletal Muscle Ryanodine Receptor: A Comparative Molecular Field Analysis

Biochemistry (Easton), 1994-05, Vol.33 (20), p.6074-6085

1994

Volltextzugriff (PDF)

Dose-Ranging Study of the Safety and Pharmacokinetics of Atrasentan in Patients with Refractory Malignancies

Clinical cancer research, 2004-07, Vol.10 (13), p.4406-4411

2004

Volltextzugriff (PDF)

A phase IIa study of ABT-263 in patients with relapsed small-cell lung cancer (SCLC)

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.7046-7046

2010

Volltextzugriff (PDF)

A phase I safety and pharmacokinetic (PK) study of navitoclax (N) in combination with docetaxel (D) in patients (pts) with solid tumors

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.2518-2518

2011

Volltextzugriff (PDF)

Combination study of navitoclax with gemcitabine (G) in patients (pts) with solid tumors

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.3067-3067

2011

Volltextzugriff (PDF)

Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced pancreatic carcinoma: A University of Chicago phase II consortium study

Annals of oncology, 1998-09, Vol.9 (9), p.1035-1037

1998

Volltextzugriff (PDF)

ABT-263 activity and safety in patients with relapsed or refractory lymphoid malignancies in particular chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.8574-8574

2009

Volltextzugriff (PDF)

Dynamic contrast enhanced MRI (DCE MRI) for Phase I anti-angiogenic trial: Comparison of the transfer constant (Ktrans) to blood flow and permeability derived by a distributed parameter model

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.3514-3514

2008

Volltextzugriff (PDF)

1 – 25 von 67

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(65)
Mit Volltextzugriff
(63)

Publikationsform

Artikel
(67)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(26)
Life Sciences & Biomedicine
(25)
Humans
(21)
Male
(17)
Oncology
(17)
Female
(16)
Aged
(15)
Biological And Medical Sciences
(14)
Medical Sciences
(14)
Middle Aged
(12)
Pharmacology. Drug Treatments
(12)
Antineoplastic Agents
(11)
Adult
(8)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(7)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(7)
Chemotherapy
(7)
Treatment Outcome
(7)
Aged, 80 And Over
(6)
Animals
(6)
Sulfonamides - Administration & Dosage
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

69 ABT-199, a Selective Small Molecule Inhibitor of Bcl-2, Exhibits Efficacy in Bcl-2 Dependent Malignancies While Sparing Platelets

Phase I Interim Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) Monotherapy for Relapsed/Refractory (R/R) Multiple Myeloma (MM)

Phase 1b Interim Results: Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib (BTZ) and Dexamethasone (Dex) in Relapsed/Refractory (R/R) Multiple Myeloma (MM)

Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: A safe combination

Investigation of the Immunogenicity of a Protein Drug Using Equilibrium Dialysis and Liquid Chromatography Tandem Mass Spectrometry Detection

Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2

Phase I Study of Eniluracil, a Dihydropyrimidine Dehydrogenase Inactivator, and Oral 5-Fluorouracil with Radiation Therapy in Patients with Recurrent or Advanced Head and Neck Cancer

Effect of Endothelin-A Receptor Blockade With Atrasentan on Tumor Progression in Men With Hormone-Refractory Prostate Cancer: A Randomized, Phase II, Placebo-Controlled Trial

Concomitant Chemoradiotherapy as Primary Therapy for Locoregionally Advanced Head and Neck Cancer

Irinotecan Activation by Human Carboxylesterases in Colorectal Adenocarcinoma Cells

Phase II studies of bryostatin-1 in patients with advanced sarcoma and advanced head and neck cancer

Differential activating and deactivating effects of natural ryanodine congeners on the calcium release channel of sarcoplasmic reticulum: evidence for separation of effects at functionally distinct sites

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Thrombospondin-1–Mimetic Angiogenesis Inhibitor ABT-510 in Patients With Advanced Cancer

Population pharmacokinetic (PK) analysis of ABT-869 in solid tumors and acute myelogenous leukemia (AML) patients

Structural Determinants of High-Affinity Binding of Ryanoids to the Vertebrate Skeletal Muscle Ryanodine Receptor: A Comparative Molecular Field Analysis

Dose-Ranging Study of the Safety and Pharmacokinetics of Atrasentan in Patients with Refractory Malignancies

A phase IIa study of ABT-263 in patients with relapsed small-cell lung cancer (SCLC)

A phase I safety and pharmacokinetic (PK) study of navitoclax (N) in combination with docetaxel (D) in patients (pts) with solid tumors

Combination study of navitoclax with gemcitabine (G) in patients (pts) with solid tumors

Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced pancreatic carcinoma: A University of Chicago phase II consortium study

ABT-263 activity and safety in patients with relapsed or refractory lymphoid malignancies in particular chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)

Dynamic contrast enhanced MRI (DCE MRI) for Phase I anti-angiogenic trial: Comparison of the transfer constant (Ktrans) to blood flow and permeability derived by a distributed parameter model

Suchergebnisse filtern